XOMA

December 21, 2018

Christmas comes early for Agenus

The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.

February 10, 2016

Roche gets back to business – R&D upgrades and downgrades

October 21, 2015

Novartis strikes again in immuno-oncology

October 06, 2015

Among smaller biopharmas, US groups take a back seat

July 23, 2015

Reports of Xoma's demise are only slightly exaggerated

June 26, 2015

Alexion’s twin approval highlights industry’s love of orphans

January 30, 2015

Upcoming events: Data from Xoma’s gevokizumab and Teva’s migraine antibody

November 07, 2013

Lilly deal hints at renewed interest in once promising pain class

October 25, 2013

Upcoming events: Xoma looks to gevokizumab and readouts at lung cancer conference